# Synthesis of Substituted Furo[3,2-e][1,2,4]triazolo[4,3-c]pyrimidines and Furo[3,2-e]tetrazolo[1,5-c]pyrimidines

Christopher C. Lockhart and J. Walter Sowell, Sr.\*

University of South Carolina, College of Pharmacy, Department of Basic Pharmaceutical Sciences, Division of Medicinal Chemistry, Columbia, SC 29208 Received January 20, 1996

# Dedicated to the memory of Professor Nicholas Alexandrou

A series of substituted furo [3,2-e][1,2,4] triazolo [4,3-c] pyrimidines and furo [3,2-e] tetrazolo [1,5-c] pyrimidines and furo [3,2-e] tetrazolo [3,2-e] tetraz idines were obtained from reactions of substituted 2-dimethylamino-4-hydrazinofuro[2,3-d]pyrimidines with orthoesters or sodium nitrite in acetic acid, respectively.

J. Heterocyclic Chem., 33, 659 (1996).

## Introduction.

Historically, a wide range of biological activities have been attributed to fused triazoles and tetrazoles. For instance, derivatives of the [1,2,4]triazolo[4,3-c]quinazoline nucleus 1 [1] are known to possess antiinflammatory [2], anxiolytic [3] and antitumor activity [4] (Figure 1). The analogous thieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidines 2 have been reported [5] and also have been investigated as potential antiinflammatory agents [6]. Treuner and Breuer [7] have prepared the pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidines 3 for study as antiinflammatory agents while the closely related pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidines 4 have been synthesized for their analgesic, CNS depressant and antipyretic properties [8]. The [1,2,4]triazolo[3,4-i]purines 5 have been pursued for their bronchodilatory activity [9] and Brown and Shinozuka [10] have used the [1,2,4]triazolo[4,3-c]pteridines 6 to potentiate the activity of antibiotics.





Figure 1.

The fused tetrazoles have been found to exhibit similar biological properties. The tetrazolo[1,5-c]quinazolines 7 have been synthesized by Hand and Baker [4] for their antitumor activity (Figure 1) while the tetrazolo[1,5-c]thieno[3,2-e]pyrimidines 8 have been reported as potential antifolates [11]. The pyrazolo[4,3-e]tetrazolo[1,5-c]pyrimidines 9 have been of interest as antimalarials [12] and the derivatives of pyrido[3,2-e]tetrazolo[1,5-c]pyrimidines 10 have been associated with anxiolytic activity [13]. Montgomery and coworkers [14] have associated the tetrazolo[5,1-i]purines 11 with the inhibition of blood platelet aggregation. We now wish to report a series of novel furo[3,2-e][1,2,4]triazolo[4,3-c]pyrimidines and furo[3,2-e]tetrazolo[1,5-c]pyrimidines.



(a) Phosgene iminium chloride, 1,2-dichloroethane; (b) Hydrazine hydrate, ethanol, reflux; (c) Trimethyl orthoformate; (d) Triethyl orthoacetate; (e) Sodium nitrite, acetic acid.

The previously reported 4,5-disubstituted-2-amino-3-cyanofurans 12a,b were available by condensation of acetoin or benzoin respectively with malononitrile under basic conditions [15] (Scheme 1). These furans were then converted to the 5,6-disubstituted-4-chloro-2-dimethylaminofuro[2,3-d]pyrimidines 13a,b by reaction with phosgene iminium chloride in 1,2-dichloroethane [16]. Displacement of the halogen by hydrazine [17] in refluxing ethanol yielded the 5,6-disubstituted-2-dimethylamino-4-hydrazinofuro[2,3-d]pyrimidines 14a,b. These compounds served as the immediate precursors for the direct synthesis of all the title compounds.

The compounds 14a,b were converted to the 8,9-disubstituted-5-dimethylaminofuro[3,2-e][1,2,4]triazolo[4,3-c]-pyrimidines 15a,b and their 3-methyl analogs 16a,b by reaction with trimethyl orthoformate and triethyl orthoacetate, respectively [6]. The 8,9-disubstituted-5-dimethylaminofuro[3,2-e]tetrazolo[1,5-c]pyrimidines 17a,b were obtained by reaction of 14a,b with sodium nitrite in acetic acid [17] (Scheme 1).

Structural assignments of all novel compounds were made on the basis of elemental analyses, nmr, infrared, and mass spectra (see Experimental).

### **EXPERIMENTAL**

Melting points were determined on an Electrothermal apparatus (capillary method) and are uncorrected. The infrared spectra were performed on a Beckmann Acculab 4 spectrophotometer using the potassium bromide technique. The tlc were performed with Baker silica plates, type Si250F. Column chromatography was performed with E.M. Science Silica Gel type 60, 40-63 µm. The proton nmr spectra were obtained on a Bruker WH-400 NMR spectrometer using deuteriochloroform as the solvent and mass spectra were obtained by a VG-70 SQ instrument. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, Georgia.

The procedures given for the syntheses of 13a-17a were utilized in the preparations of 13b-17b, respectively.

4-Chloro-2-dimethylamino-5,6-dimethylfuro[2,3-d]pyrimidine (13a).

Phosgene iminium chloride (0.041 mole, 6.61 g) was added to a solution of 2-amino-3-cyano-4,5-dimethylfuran (12a) (0.033 mole, 4.62 g) in 150 ml of 1,2-dichloroethane. The reaction mixture was stirred for two days at 40-50° under a calcium chloride drying tube and then washed twice with sodium bicarbonate. The organic layer was concentrated *in vacuo* to yield a dark red solid. The product was obtained by column chromatography with a dichloromethane mobile phase and recrystallization (methanol) yielded (3.05 g, 41%) a white powder, tlc  $R_f$ , hexanes:ethyl acetate (9:1), 0.45, mp 86-88°; ir: v 2860, 1610, 1530, 1400, 1350, 1290, 1250, 1050, 1000 cm<sup>-1</sup>;  $^1$ H-nmr:  $\delta$  2.2 (s, 3H, 5-CH<sub>3</sub>), 2.3 (s, 3H, 6-CH<sub>3</sub>), 3.2 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>); ms: ei (m/z) 225 (M<sup>+</sup>).

Anal. Calcd. for C<sub>10</sub>H<sub>12</sub>ClN<sub>3</sub>O: C, 53.22; H, 5.36; Cl, 15.71; N, 18.62. Found: C, 53.05; H, 5.39; Cl, 15.60; N, 18.50.

4-Chloro-2-dimethylamino-5,6-diphenylfuro[2,3-d]pyrimidine (13b).

Recrystallization from methanol:acetone (3:1) yielded (9.52 g, 54%) white needles, tlc  $R_f$ , hexanes:ethyl acetate (9:1), 0.57, mp 205-207°; ir: v 3000, 2910, 1620, 1560, 1540, 1410, 1350, 1290 cm<sup>-1</sup>; <sup>1</sup>H-nmr:  $\delta$  3.2 (s, 6H, 2-N(CH<sub>3</sub>)<sub>2</sub>), 7.3 (m, 10H, Ar-H); ms: ei (m/z) 349 (M<sup>+</sup>).

Anal. Calcd. for C<sub>20</sub>H<sub>16</sub>ClN<sub>3</sub>O: C, 68.67; H, 4.61; Cl, 10.14; N, 12.01. Found: C, 68.67; H, 4.64; Cl, 10.24; N, 11.91.

2-Dimethylamino-4-hydrazino-5,6-dimethylfuro[2,3-d]pyrimidine (14a).

A solution of hydrazine hydrate (0.022 mole, 1.10 g) and 4-chloro-2-dimethylamino-5,6-dimethylfuro[2,3-d]pyrimidine (13a) (0.01 mole, 2.25 g) in 70 ml of absolute ethanol was refluxed for 24 hours. The solvent was removed in vacuo and the residue was recrystallized from methanol to yield (1.20 g, 54%) off-white crystals, tlc R<sub>f</sub>, hexanes:ethyl acetate:dichloromethane (2:1:1), 0.25, mp 193-195°; ir: v 3390, 3280, 2900, 2850, 1580, 1550, 1460, 1420, 1380 cm<sup>-1</sup>;  $^{1}$ H-nmr:  $\delta$  2.25 (s, 3H, 6-CH<sub>3</sub>), 2.2 (s, 3H, 5-CH<sub>3</sub>), 3.2 (s, 6H, 2-N(CH<sub>3</sub>)<sub>2</sub>), 4.4 (s, 2H, 4-NH<sub>2</sub>), 5.7 (s, 1H, 4-NH); ms: ei (m/z) 221 (M<sup>+</sup>).

Anal. Calcd. for  $C_{10}H_{15}N_5O$ : C, 54.28; H, 6.83; N, 31.66. Found: C, 54.36; H, 6.87; N, 31.58.

2-Dimethylamino-4-hydrazino-5,6-diphenylfuro[2,3-d]pyrimidine (14b).

Recrystallization from methanol yielded (3.98 g, 89%) white needles, tlc  $R_{\rm f}$ , hexanes:ethyl acetate:dichloromethane (2:1:1), 0.45, mp 215-217°; ir: v 3120, 3050, 2850, 1590, 1550, 1400, 1340, 1210 cm<sup>-1</sup>; <sup>1</sup>H-nmr:  $\delta$  3.2 (s, 6H, 2-N(CH<sub>3</sub>)<sub>2</sub>), 4.4 (s, 2H, 4-NH<sub>2</sub>), 5.8 (s, 1H, 4-NH), 7.4 (m, 10H, Ar-H); ms: ei (m\z) 345 (M<sup>+</sup>).

Anal. Calcd. for  $C_{20}H_{19}N_5O$ : C, 69.54; H, 5.54; N, 20.28. Found: C, 69.54; H, 5.56; N, 20.35.

5-Dimethylamino-8,9-dimethylfuro[3,2-e][1,2,4]triazolo[4,3-c]-pyrimidine (15a).

A solution of 2-dimethylamino-4-hydrazino-5,6-dimethylfuro[2,3-d]pyrimidine (14a) (0.0017 mole, 0.370 g) in trimethyl orthoformate (25 ml) was stirred at 70° for six hours and then cooled overnight. It was concentrated *in vacuo* and recrystallized from ethyl acetate and hexanes (3:1) to yield (0.190 g, 51%) white needles, tlc  $R_f$ , ethyl acetate, 0.20, mp 155-157°; ir: v 2910, 2880, 1620, 1590, 1550, 1470, 1390, 1370 cm<sup>-1</sup>; <sup>1</sup>H-nmr:  $\delta$  2.38 (s, 3H, 9-CH<sub>3</sub>), 2.42 (s, 3H, 8-CH<sub>3</sub>), 3.19 (s, 6H, 5-N(CH<sub>3</sub>)<sub>2</sub>), 8.82 (s, 1H, 3-H); ms: ei (m\z) 231 (M<sup>+</sup>).

*Anal.* Calcd. for C<sub>11</sub>H<sub>13</sub>N<sub>5</sub>O•0.25H<sub>2</sub>O: C, 56.04; H, 5.77; N, 29.71. Found: C, 55.87; H, 5.82; N, 29.61.

5-Dimethylamino-8,9-diphenylfuro[3,2-e][1,2,4]triazolo[4,3-c]-pyrimidine (15b).

After cooling the reaction mixture in the freezer, the precipitate was collected by filtration and recrystallization (methanol) yielded (0.695 g, 66%) a white powder, tlc  $R_f$ , ethyl acetate, 0.25, mp 308-310° dec; ir: v 3090, 3010, 2960, 1620, 1580, 1500, 1480, 1410, 1340 cm<sup>-1</sup>; <sup>1</sup>H-nmr:  $\delta$  3.3 (s, 6H, 5-N(CH<sub>3</sub>)<sub>2</sub>), 7.4 (m, 10H, Ar-H), 8.9 (s, 1H, 3-H); ms: ei (m/z) 355 (M<sup>+</sup>).

Anal. Calcd. for  $C_{21}H_{17}N_5O$ : C, 70.97; H, 4.82; N, 19.71. Found: C, 71.04; H, 4.86; N, 19.63.

5-Dimethylamino-3,8,9-trimethylfuro[3,2-e][1,2,4]triazolo-[4,3-c]pyrimidine (16a).

A solution of 2-dimethylamino-4-hydrazino-5,6-dimethylfuro[2,3-d]pyrimidine (14a) (0.005 mole, 1.21 g) in triethyl orthoacetate (60 ml) was stirred at 70° for twenty-four hours and then concentrated in vacuo to yield a brown solid. Recrystallization from ethyl acetate yielded (0.492 g, 40%) white needles, tlc  $R_f$ , ethyl acetate, 0.25, mp 235-237°; ir: v 2900, 2840, 2780, 1620, 1530, 1500, 1350, 1330, 1290 cm<sup>-1</sup>;  $^1H$ -nmr:  $\delta$  2.40 (s, 3H, 9-CH<sub>3</sub>), 2.41 (s, 3H, 8-CH<sub>3</sub>), 2.88 (s, 3H, 3-CH<sub>3</sub>), 2.95 (s, 6H, 5-N(CH<sub>3</sub>)<sub>2</sub>); ms: ei (m/z) 245 (M<sup>+</sup>).

Anal. Calcd. for C<sub>12</sub>H<sub>15</sub>N<sub>5</sub>O•0.20H<sub>2</sub>O: C, 57.91; H, 6.24; N, 28.14. Found: C, 58.11; H, 6.24; N, 28.27.

5-Dimethylamino-3-methyl-8,9-diphenylfuro[3,2-e][1,2,4]triazolo[4,3-e]pyrimidine (16b).

Recrystallization from methanol:chloroform (4:1) yielded (0.566 g, 61%) tan needles, tlc  $R_f$ , ethyl acetate, 0.38, mp 224-226°; ir: v 3110, 3020, 2970, 1610, 1550, 1530, 1440, 1390, 1270, 1230 cm<sup>-1</sup>; <sup>1</sup>H-nmr:  $\delta$  3.0 (s, 3H, 3-CH<sub>3</sub>), 3.3 (s, 6H, 5-N(CH<sub>3</sub>)<sub>2</sub>), 7.2 (m, 10H, Ar-H); ms: ei (m/z) 369 (M<sup>+</sup>).

Anal. Calcd. for  $C_{22}H_{19}N_5O$ : C, 71.53; H, 5.18; N, 18.96. Found: C, 71.36; H, 5.21; N, 18.88.

5-Dimethylamino-8,9-dimethylfuro[3,2-e]tetrazolo[1,5-c]pyrimidine (17a).

A solution of 2-dimethylamino-4-hydrazino-5,6-dimethylfuro[2,3-d]pyrimidine (14a) (0.005 mole, 1.10 g) and sodium nitrite (0.005 mole, 0.345 g) in acetic acid (50 ml) was stirred at room temperature for twenty-four hours. Cold distilled water was added and the precipitate was collected by filtration. Recrystallization from methanol yielded (0.495 g, 33%) white needles, tlc R<sub>f</sub>, hexanes:ethyl acetate (9:1), 0.50, mp 92-94°; ir: v 3260, 1620, 1540, 1400, 1360, 1320, 1280, 1230 cm<sup>-1</sup>; <sup>1</sup>H-nmr: δ 2.1 (s, 3H, 9-CH<sub>3</sub>), 2.21 (s, 3H, 8-CH<sub>3</sub>), 3.2 (s, 6H, 5-N(CH<sub>3</sub>)<sub>2</sub>); ms: ei (m/z) 232 (M<sup>+</sup>).

Anal. Calcd. for  $C_{10}H_{12}N_6O$ : C, 51.71; H, 5.21; N, 36.19. Found: C, 51.45; H, 5.30; N, 35.93.

5-Dimethylamino-8,9-diphenylfuro[3,2-e]tetrazolo[1,5-c]pyrimidine (17b).

Recrystallization in methanol:chloroform (3:1) yielded (0.762 g, 71%) yellow needles, tlc R<sub>f</sub>, hexanes:ethyl acetate:dichloromethane

(2:1:1), 0.80, mp 168-170°; ir: v 3100, 3070, 2890, 1590, 1560, 1480, 1300, 1240 cm<sup>-1</sup>;  $^{1}$ H-nmr:  $\delta$  3.1 (s, 6H, 5-N(CH<sub>3</sub>)<sub>2</sub>), 7.1 (m, 10H, Ar-H); ms: ei (m/z) 356 (M<sup>+</sup>).

Anal. Calcd. for  $C_{20}H_{16}N_6O$ : C, 67.40; H, 4.52; N, 23.58. Found: C, 67.17; H, 4.58; N, 23.79.

### REFERENCES AND NOTES

- [1] S. Stankovsky and M. Sokyrova, Collect. Czech. Chem. Commun., 49, 1795 (1984).
- [2] F. G. Kathawala, U.S. Patent 3,850,932 (1974); Chem. Abstr., 75, 140175d (1975).
- [3] G. E. Hardtmann, F. G. Kathawala, U.S. Patent 4,053,600 (1977); Chem. Abstr., 88, 22970k (1978).
  - [4] E. S. Hand and D. C. Baker, Can. J. Chem., 62, 2570 (1984).
- [5] M. Robba, M. Cugnon de Sevricourt and J. M. Leconte, J. Heterocyclic Chem., 12, 525 (1975).
- [6] C. J. Shishoo, M. B. Devani, G. V. Ullas, S. Ananhan and V. S. Bhadti, J. Heterocyclic Chem., 18, 43 (1981).
- [7] U. D. Treuner and H. Breuer, U.S. Patent 4,053,474 (1976);Chem. Abstr., 88, 37826s, (1978).
- [8] K. Noda, A. Nakagawa, Y. Nakajima and H. Ide, Japanese Patent 85,194 (1977); Chem. Abstr., 88, 50908q (1978).
- [9] F. Suzuki, J. Shimada, K. Ohmori, H. Manabe and K. Kubo, European Patent 417,790 (1991); Chem. Abstr., 91, 91963y (1991).
- [10] D. J. Brown and K. Shinozuka, Aust. J. Chem., 34, 189 (1981).
- [11] C. J. Shishoo and K. S. Jain, J. Heterocyclic Chem., 29, 883 (1992).
- [12] G. Franco, L. Maria and P. Giueseppe, J. Heterocyclic Chem., 26, 613 (1989).
- [13] L. Godefroy, A. Decormeille and G. Queguiner, Chem. Abstr., 84, 91461n (1974).
- [14] J. A. Montgomery, A. G. Laseter and K. Hewson, J. Heterocyclic Chem., 11, 211 (1974).
  - [15] K. Gewald, Chem. Ber., 99, 1002 (1966).
- [16] B. Kokel, G. Menichi and M. Hubert-Habart, Tetrahedron Letters, 25, 1557 (1984).
- [17] M. R. Chaurasia and S. Sharma, Heterocycles, 14, 1759 (1980).